Retirees Rely These Safe High-Yield Monthly Stocks
As markets stay choppy in early 2026, retirees turn to monthly dividend stocks for predictable income and capital pre...
Using Stablecoins As Cash Reserve
Stablecoins offer a cash-like reserve with stability and accessibility. This intro covers building a practical cash reserve using stablecoins.
20,367 articles
Opendoor Technologies Jumps on IBuying Surge: What It Means
Opendoor Technologies reports a sharp uptick in iBuying activity, with 1,706 homes bought in the latest quarter, lift...
What Investors Should About AI Risk and Opportunity
Investors grapple with AI-driven disruption as markets remain volatile in early 2026. Experts outline disciplined ste...
Merck Stock Jumps, but Reddit Traders Grow Cautious
Merck stock jumps on a major restructuring, but Reddit sentiment shows growing skepticism as investors weigh Keytruda...
Dennis Quaid Once Played: Money Lessons From Fame Today
Fame can boost earnings and complicate finances in equal measure. This article uses the idea that dennis quaid once p...
Moderna and Ross Stores Lead Market Gainers on Wednesday
Moderna and Ross Stores surged midweek on distinct catalysts: a patent settlement clearing a key overhang for Moderna...
Investors Need Know This: AMD's Pullback Points to AI Upside
A recent price retreat for AMD has more to do with market nerves than a broken thesis. This article lays out why inve...
Risks That Could Erode Walmart's Long-Term Competitive Edge
Walmart has built a durable model, but three looming risks could erode its long-term edge. This guide breaks down tho...
PennyMac Launches Comprehensive Non-QM Product Suite
PennyMac’s Third-Party Origination unit rolls out a seven-program non-QM suite to broaden options for borrowers with ...
2036, Investors Will Regret Missing This Multibagger
Long-term investors chase multibagger dreams. This article explores a high-potential biotech setup with 26 late-stage...
Dalio Warns of a Dangerous Phase in the Big Cycle Today
A senior macro investor warns that the global order is entering a perilous stage of the Big Cycle, likely to test mar...
Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status